The Paper's reporter Li Xiaoxiao
On June 3, Yunnan Watson Biotechnology Co., Ltd. (Watson Biotechnology, 300142) announced that it received a "Notification Letter" issued by Li Yunchun, chairman of the company, and Huang Zhen, vice chairman of the company, on June 2, Due to the adjustment of shareholding methods, Li Yunchun and Huang Zhen transferred part of the shares held by Watson Bio to Chengdu Xiyun Enterprise Management Partnership (Limited Partnership) (hereinafter referred to as "Chengdu Xiyun") at a price of 69.84 yuan per share through a block transaction.
According to the announcement, Li Yunchun transferred 2,536,747 shares, with a transfer ratio of 0.16%, and Huang Zhen transferred 1 million shares, with a transfer ratio of 0.06%. According to the above data, the two transferred a total of more than 3.53 million shares, with a total value of more than 247 million yuan.
The announcement said that the share transfer of Li Yunchun and Huang Zhen did not violate relevant regulations and relevant commitments. Regarding the above-mentioned equity transfer, the surging news reporter contacted the secretary of the board of directors of Watson Biology, who said that Chengdu Xiyun is a platform established by Li Yunchun and Chengdu State-owned Assets, and "the shares are transferred to increase control." ”
According to tianyancha data, Chengdu Xiyun was established on March 21 this year, with a registered capital of 4.002 billion yuan, and its business scope includes general projects: enterprise management, enterprise management consulting, marketing planning.
According to the partners and capital contributions of Chengdu Xiyun disclosed in the announcement, Li Yunchun has the largest proportion of capital contribution, reaching 69.74%, Huangzhen has contributed 6.97%, and the second largest investor is Chengdu Wuhou Capital Investment Management Group Co., Ltd. According to equity penetration, the controlling shareholder behind it is the State-owned Assets Supervision and Administration and Financial Work Bureau of Wuhou District, Chengdu. It is worth noting that the executive partner of Chengdu Xiyun is Yuxi Wogu Investment Management Co., Ltd., which was established in 2016, and the company's investment ratio to Chengdu Xiyun is 0.02%, and the data of Tianyancha shows that the company's suspected controlling person is also Li Yunchun.
Partners and capital contributions of Chengdu Xiyun
In fact, this is not the first time that Li Yunchun has transferred the equity of Watson Biology to Chengdu Xiyun through a block transaction. On May 17 this year, Watson Biologics announced that Li Yunchun transferred 9.53 million shares of Watson Bio, accounting for 0.61% of the total share capital of Watson Bio, to Chengdu Xiyun, whose control and acted as the representative of the executive partner, at a price of 68.20 yuan per share.
According to the announcement on May 17, after the share transfer, the number of shares of Watson Biologics in which Li Yunchun has a total interest has not changed, and it is still 48,266,988 shares, accounting for 3.08% of the total share capital of Watson Biologics, including 9.53 million shares held by Chengdu Xiyun. Chengdu Xiyun is controlled by Li Yunchun, that is to say, after the transfer of equity, Li Yunchun changed from directly holding Watson Biological Shares to Holding Watson Biological Shares through Chengdu Xiyun.
According to the announcement on June 3, Li Yunchun held 38,736,988 shares, accounting for 2.47% of the total share capital, before the share transfer and 36,200,241 shares, accounting for 2.31% of the total share capital. Correspondingly, after the transfer, the total number of shares held by Chengdu Xiyun in Watson Bio increased from 9.53 million shares to 13,066,747 shares, accounting for 0.83% of the total share capital, all of which are unlimited sale conditional shares.
Chengdu Xiyun held shares before and after the transfer of shares on June 2
According to the official website, Watson Bio was founded in 2001, headquartered in Kunming, Yunnan Province, and was listed on the Growth Enterprise Market of the Shenzhen Stock Exchange in November 2010. Since the outbreak of the new crown epidemic, Watson Bio has attracted much attention from the outside world because of its participation in the research and development of the new crown vaccine.
On May 28, Watson Bio announced that the recombinant novel coronavirus vaccine (chimpanzee adenovirus vector) jointly developed by the company, Tsinghua University and Tianjin Medical University, has obtained drug clinical trial approval. In addition, Watson Biology and Aibo Biologics are also conducting research and development of the MNA new crown vaccine, according to the Central Broadcasting Network reported on April 13, the vaccine has entered the end of phase II clinical trials, and will work closely with Tigermed to carry out overseas phase III clinical trials in May.
As of the close of trading on June 3, Watson Bio reported 64.33 yuan / share, down 4.54%, with a market value of 100.75 billion yuan.
Editor-in-Charge: Wang Jie
Proofreader: Yan Zhang